S&P Futures
5,884.75 -11.50 (-0.20%) Dow Futures
43,111.00 -66.00 (-0.15%) Nasdaq Futures
20,465.25 -54.25 (-0.26%) Russell 2000 Futures
2,248.50 -7.00 (-0.31%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,748.90 +10.00 (+0.37%)
After hours:
| Previous Close | 0.5800 |
| Open | 1.6700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0400 - 1.7900 |
| 52 Week Range | 0.3020 - 134.6800 |
| Volume | |
| Avg. Volume | 3,482,953 |
| Market Cap | 3.865M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.02 |
| EPS (TTM) | 57.0700 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireGRI Bio Announces Exercise of Warrants
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 762,236 shares of the Company’s common stock, having an original exercise price of $14.30
- GlobeNewswire
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q4 2024 and topline data in Q1 2025 Data presented at the 22nd International Colloquium on Lung and Airway Fibrosis LA JOLLA, CA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “C
